SCHEMBL9890761

SCHEMBL9890761

Cc1ccc(-c2ccccc2)c(CC(N)=O)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.47
ICMT O60725 7/20 0.46
HDAC7 Q8WUI4 1/20 0.45
PTGS1 P23219 1/20 0.45
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
NFKB1 P19838 1/20 0.40
STAT1 P42224 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
BCAT2 O15382 1/20 0.40
ACACA Q13085 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890724 0.87 PTGDR2 (0.50) PTGDR2ICMTHDAC7PTGS1KDM4E
SCHEMBL9890663 0.87 PTGS1 (0.59) PTGDR2HDAC7PTGS1GAA
SCHEMBL9890778 0.84 GRM2 (0.48) PTGDR2ICMTKDM4EALDH1A1KMT2A
SCHEMBL9890783 0.84 ICMT (0.50) ICMTKMT2ANPC1NFKB1RAB9A
SCHEMBL9890763 0.81 HDAC7 (0.47) PTGDR2HDAC7PTGS1ALDH1A1GAA
SCHEMBL9485935 0.81 LMNA (0.45) PTGDR2HDAC7PTGS1ALDH1A1KMT2A
SCHEMBL2391307 0.81 FFAR1 (0.49) PTGDR2ICMTPTGS1KMT2A
SCHEMBL9890727 0.81 FFAR1 (0.49) PTGDR2ALDH1A1KMT2AHPGD
SCHEMBL9890726 0.80 PLA2G10 (0.52) KDM4EALDH1A1KMT2AHPGD
SCHEMBL9485214 0.79 PDCD1 (0.53) PTGDR2HDAC7PTGS1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885ICMT 2894/4885HDAC7 217/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885ICMT 2894/4885HDAC7 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.